Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Ibrahim FayadPhilippe CiaisMartin SchwartzJean-Pierre WigneronNicolas BaghdadiAurélien de TruchisAlexandre d'AspremontFrederic FrappartSassan SaatchiEwan SeanAgnes Pellissier-TanonHassan Bazzi
• Organismes : Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Contrôles des cycles biogéochimiques terrestres Kayrros Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Contrôles des cycles biogéochimiques terrestres Interactions Sol Plante Atmosphère Territoires, Environnement, Télédétection et Information Spatiale Kayrros Kayrros Interactions Sol Plante Atmosphère Jet Propulsion Laboratory Kayrros Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation des Surfaces et Interfaces Continentales Mathématiques et Informatique Appliquées
• Publié dans Remote Sensing of Environment le 28/10/2020

---

Résumé : Accurate and timely monitoring of forest canopy height is critical for assessing forest dynamics, biodiversity, carbon sequestration as well as forest degradation and deforestation. Recent advances in deep learning techniques, coupled with the vast amount of spaceborne remote sensing data offer an unprecedented opportunity to map canopy height at high spatial and temporal resolutions. Current techniques for wall-to-wall canopy height mapping correlate remotely sensed information from optical and radar sensors in the 2D space to the vertical structure of trees using lidar's 3D measurement abilities serving as height proxies. While studies making use of deep learning algorithms have shown promising performances for the accurate mapping of canopy height, they have limitations due to the type of architectures and loss functions employed. Moreover, mapping canopy height over tropical forests remains poorly studied, and the accurate height estimation of tall canopies is a challenge due to signal saturation from optical and radar sensors, persistent cloud cover, and sometimes limited penetration capabilities of lidar instruments. In this study, we map heights at 10 m resolution across the diverse landscape of Ghana with a new vision transformer (ViT) model, dubbed Hy-TeC, optimized concurrently with a classification (discrete) and a regression (continuous) loss function. This model achieves significantly higher accuracy than previously employed convolutional-based approaches (ConvNets) optimized with only a continuous loss function. Hy-TeC results show that our proposed discrete/continuous loss formulation significantly increases the sensitivity for very tall trees (i.e., > 35 m). Overall, Hy-TeC has significantly reduced bias (0.8 m) and higher accuracy (RMSE = 6.6 m) over tropical forests for which other approaches show poorer performance and oftentimes a saturation effect. The height maps generated by Hy-TeC also have better ground sampling distance and better sensitivity to sparse vegetation. Over these areas, Hy-TeC showed an RMSE of 3.1 m in comparison to a reference dataset while the baseline ConvNet model had an RMSE of 4.3 m. Hy-TeC, which was used to generate a height map of Ghana using free and open access remotely sensed data with Sentinel-2 and Sentinel-1 images as predictors and GEDI height measurements as calibration data, has the potential to be used globally.

---

Fichiers liés : 1-s2.0-S0034425723004972-am.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Victor de LédinghenClaire Fougerou-LeurentEstelle Le PabicStanislas PolDulce AlfaiateKarine LacombeMarie-Noëlle HilleretCaroline Lascoux-CombeAnne MinelloEric BillaudIsabelle RosaAnne GervaisVlad RatziuNathalie Ganne-CarriéGeorges-Philippe PageauxVincent LeroyVéronique Loustaud-RattiPhilippe MathurinJulie ChasCaroline JezequelSophie MétivierJérôme DumortierJean-Pierre ArpurtTarik AsselahBruno RocheAntonia Le GruyerMarc-Antoine ValantinCaroline ScholtesEmmanuel GordienChristelle TualAmel KortebiFatoumata CoulibalyEric RosenthalMiroslava Subic-LevreroDominique RoulotFabien ZoulimFrançois RaffiLaurent AlricPatrick MiailhesAlbert TranChristiane SternXavier CausseSimona TriponGhassan RiachiOlivier ChazouillèresArmando AbergelLouis D’alterocheJérôme GournayGarance LagadicPatrizia M. CarrieriSégolène BrichlerMartin SiguierJessica KrauseJuliette FoucherSouad Ben AliMagdalena MeszarosAnne VarautValérie Canva
• Organismes : Bordeaux population health BoRdeaux Institute of onCology Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Hôpital Cochin [AP-HP] Assistance publique - Hôpitaux de Paris (AP-HP) Institut Cochin Université de Genève = University of Geneva Hôpital de la Croix-Rousse [CHU - HCL] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Hopital Saint-Louis [AP-HP] Lipides - Nutrition - Cancer [Dijon - U1231] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Intercommunal de Créteil AP-HP - Hôpital Bichat - Claude Bernard [Paris] Assistance publique - Hôpitaux de Paris (AP-HP) Hôpital Avicenne [AP-HP] Hôpital Saint Eloi [CHU Montpellier] CHU Henri Mondor [Créteil] Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation Centre Hospitalier Régional Universitaire [CHU Lille] Institute for Translational Research in Inflammation - U 1286 CHU Tenon [AP-HP] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Service Chirurgie viscérale et digestive [CHU Toulouse] Centre de recherche sur l'Inflammation Institut Pierre Louis d'Epidémiologie et de Santé Publique Hospices Civils de Lyon Hôpital de la Croix-Rousse [CHU - HCL] Université Claude Bernard Lyon 1 Centre de Recherche en Cancérologie de Lyon Centre de Recherche en Cancérologie de Lyon Centre de Recherche en Cancérologie de Lyon
• Publié dans JHEP Reports Innovation in Hepatology le 07/09/2020

---

Résumé : Background and AimsIn France, Bulevirtide (BLV) was available in September 2019 through an early access program to treat patients with hepatitis Delta virus (HDV). The aim of this analysis was to evaluate the efficacy and safety of BLV in HIV patients with HDV coinfection.Patients and methodsPatients received BLV 2 mg +/- pegylated interferon (pegIFNα) according to the physician’s decision. The primary endpoint (per-protocol analysis) was the virological response rate at week 48, defined as the proportion of patients with undetectable serum HDV-RNA or HDV-RNA decline > 2 log10 IU/mL from baseline.ResultsCharacteristics of the 38 patients were as follow: 28 male, mean age 47.7 years, mean baseline HDV-RNA viral load 5.7 ± 1.2 log10 IU/ml. Median HIV viral load and mean CD4 count were 32 (30 - 65) cp/ml and 566 ± 307/mm3, respectively. Eight patients stopped treatment before week 48. At W48, 10 of 19 patients (52.6%) in the 2 mg BLV group, and 5 of 7 patients (71.4%) in the 2 mg BLV + pegIFNα group had reached virological response (no HDV-RNA available in 4 patients). At W48, 7/19 patients in the 2 mg BLV group, and 3/6 patients in the 2 mg BLV + pegIFNα group had combined response (virological response and normal ALT level).ConclusionAdults living with HIV coinfected with HDV can be treated by BLV with a virological response in more than 50% of patients. The combination of BLV and pegIFNα showed a strong virological response.

---

Fichiers liés : PIIS2589555924000582.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Géraldine AndrodiasLouise NoroyDimitri PsimarasCristina BirzuJean PelletierYsoline BeigneuxPierre BrangerJonathan CironYannick DananchetRaphael DepazCaroline Froment TiliketeLaurence GignouxClara Grosset-JaninBastien JoubertPhilippe KerschenArnaud KwiatkowskiChristine Lebrun-FrenayElisabeth MaillartAurelien MaureillePhilippe NicolasThomas RouxRomain MarignierSandra Vukusic
• Organismes : Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Forgetting Processes and Cortical Dynamics Plateforme de Neurobiologie Moléculaire, Cellulaire et Tissulaire Hospices Civils de Lyon Université Claude Bernard Lyon 1 Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle
• Publié dans Neurology Neuroimmunology & Neuroinflammation le 28/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Mathieu MévelVirginie PichardMohammed BouzelhaDimitri Alvarez-DortaPierre-Alban LalysNathalie ProvostMarine AllaisAlexandra MendesElodie LandagarayJean‐baptiste DucloyerEstelle ToublancAnne GalyNicole BrumentGaëlle M. LefevreSébastien G. GouinCarolina IsiegasGuylène Le MeurT. CroninCaroline Le GuinerMichel WeberPhilippe P. MoullierEduard AyusoSebastien G. GouinOumeya Adjali
• Organismes : Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Coave Therapeutics Coave Therapeutics Coave Therapeutics Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089
• Publié dans Molecular Therapy - Methods and Clinical Development le 26/10/2020

---

Résumé : Inherited retinal diseases are a leading and untreatable cause of blindness and are therefore candidate diseases for gene therapy. Recombinant vectors derived from adeno-associated virus (rAAV) are currently the most promising vehicles for in vivo therapeutic gene delivery to the retina. However, there is a need for novel AAV-based vectors with greater efficacy for ophthalmic applications, as underscored by recent reports of dose-related inflammatory responses in clinical trials of rAAV-based ocular gene therapies. Improved therapeutic efficacy of vectors would allow for decreases in the dose delivered, with consequent reductions in inflammatory reactions. Here, we describe the development of new rAAV vectors using bioconjugation chemistry to modify the rAAV capsid, thereby improving the therapeutic index. Covalent coupling of a mannose ligand, via the formation of a thiourea bond, to the amino groups of the rAAV capsid significantly increases vector transduction efficiency of both rat and nonhuman primate retinas. These optimized rAAV vectors have important implications for the treatment of a wide range of retinal diseases.

---

Fichiers liés : 1-s2.0-S2329050124000032-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Mathieu MévelVirginie PichardMohammed BouzelhaDimitri Alvarez-DortaPierre-Alban LalysNathalie ProvostMarine AllaisAlexandra MendesElodie LandagarayJean‐baptiste DucloyerEstelle ToublancAnne GalyNicole BrumentGaëlle LefevreSebastien G. GouinCarolina IsiegasGuylène Le MeurT. CroninCaroline Le GuinerMichel WeberPhilippe MoullierEduard AyusoDavid DeniaudOumeya Adjali
• Organismes : Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Coave Therapeutics Coave Therapeutics Coave Therapeutics Nantes Université Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Nantes Université Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation Laboratoire de Thérapie Génique Translationnelle des Maladies Génétiques / Translational Research in Gene Therapy - UMR_S 1089 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
• Publié dans Molecular Therapy - Methods and Clinical Development le 26/10/2020

---

Résumé : Inherited retinal diseases are a leading and untreatable cause of blindness and are therefore candidate diseases for gene therapy. Recombinant vectors derived from adeno-associated virus (rAAV) are currently the most promising vehicles for in vivo therapeutic gene delivery to the retina. However, there is a need for novel AAV-based vectors with greater efficacy for ophthalmic applications, as underscored by recent reports of dose-related inflammatory responses in clinical trials of rAAV-based ocular gene therapies. Improved therapeutic efficacy of vectors would allow for decreases in the dose delivered, with consequent reductions in inflammatory reactions. Here, we describe the development of new rAAV vectors using bioconjugation chemistry to modify the rAAV capsid, thereby improving the therapeutic index. Covalent coupling of a mannose ligand, via the formation of a thiourea bond, to the amino groups of the rAAV capsid significantly increases vector transduction efficiency of both rat and nonhuman primate retinas. These optimized rAAV vectors have important implications for the treatment of a wide range of retinal diseases.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Xavier DeffieuxMarie-Aimée Perrouin-VerbeSandrine Campagne-LoiseauLaurence DononAmélie LevesqueJérome RigaudNadja StivaletAurélien VenaraThibault ThubertAdrien VidartPierre-Olivier BossetChristine Revel-DelhomJean-Philippe LucotJean François Hermieu
• Organismes : Université Paris-Saclay AP-HP - Hôpital Antoine Béclère [Clamart] Nantes Université Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Estaing [Clermont-Ferrand] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Nantes Université Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Université Paris Cité Université d'Angers Centre Hospitalier Universitaire d'Angers Nantes Université Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital Foch [Suresnes] Hôpital Foch [Suresnes] Hôpital Foch [Suresnes] Université catholique de Lille Université Paris Cité
• Publié dans European Journal of Obstetrics & Gynecology and Reproductive Biology le 30/10/2020

---

Résumé : Complications associated with pelvic organ prolapse (POP) surgery using a synthetic non-absorbable mesh are uncommon (<5%) but may be severe and may hugely diminish the quality of life of some women. In drawing up these multidisciplinary clinical practice recommendations, the French National Authority for Health (Haute Autorité de santé, HAS) conducted an exhaustive review of the literature concerning the diagnosis, prevention, and management of complications associated with POP surgery using a synthetic mesh. Each recommendation for practice was allocated a grade (A,B or C; or expert opinion (EO)), which depends on the level of evidence (clinical practice guidelines).

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Philippe Van De PerreGabriella ScarlattiPenny L MooreJean-Pierre MolesNicolas NagotThorkild TylleskärGlenda GrayAmeena Goga
• Organismes : Pathogenesis and Control of Chronic and Emerging Infections IRCCS Ospedale San Raffaele [Milan, Italy] University of the Witwatersrand [Johannesburg] National Institute for Communicable Diseases [Johannesburg] Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections University of Bergen South African Medical Research Council [Cape Town, South Africa] South African Medical Research Council [Cape Town, South Africa] University of Pretoria [South Africa]
• Publié dans Immunity, Inflammation and Disease le 26/10/2020

---

Résumé : Passive immunoprophylaxis with broadly neutralizing monoclonal antibodies (bNAbs) could be a game changer in the prevention of human immunodeficiency virus (HIV) acquisition. The prevailing view is that available resources should be focused on identifying a fixed combination of at least three bNAbs for universal use in therapeutic and preventive protocols, regardless of target populations or routes of transmission. HIV transmission through breastfeeding is unique: it involves free viral particles and cell‐associated virus from breast milk and, in the case of acute/recent maternal infection, a viral population with restricted Env diversity. HIV transmission through breastfeeding in high incidence/prevalence areas could potentially be eliminated by subcutaneous administration to all newborns of one or two long‐acting bNAbs with extended breadth, high potency, and effector properties (ADCC, phagocytosis) against circulating HIV strains.

---

Fichiers liés : Immunity Inflam Disease - 2024 - Van de Perre - Preventing breast milk HIV transmission using broadly neutralizing.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Lina JeantinEdouard JanuelPierre LabaugeElisabeth MaillartJérôme de SèzeHélène ZéphirJean PelletierPhilippe KerschenDamien BiottiOlivier HeinzlefLaurent GuillotonCaroline BensaMarie ThéaudinSandra VukusicOlivier CasezAude MauroussetDavid-Axel LaplaudEric BergerChristine Lebrun-FrenayBertrand BourrePierre BrangerBruno StankoffPierre ClavelouEric ThouvenotEric ManchonThibault MoreauFrançois SellalMickaël ZedetCaroline PapeixCéline Louapre
• Organismes : Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut des Neurosciences de Montpellier Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] CIC Strasbourg Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Centre Hospitalier Régional Universitaire [CHU Lille] Service de neurophysiologie clinique [Hôpital de la Timone - APHM] Hôpital Kirchberg [Luxembourg] Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Association des Neurologues Libéraux de Langue Française Service de neurologie [Hôpital Fondation Adolphe de Rothschild] Université de Lausanne = University of Lausanne Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Team 5 : Neuroinflammation, mechanisms, therapeutic options (NEMO) CHU Rouen Service de Neurologie [CHU Caen] CHU Saint-Antoine [AP-HP] CHU Clermont-Ferrand Institut de Génomique Fonctionnelle Université de Strasbourg CHU Henri Mondor [Créteil] Service de neurologie [Hôpital Fondation Adolphe de Rothschild] Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
• Publié dans Multiple Sclerosis Journal le 31/10/2020

---

Résumé : Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022. Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity. Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave ( p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25–1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51–2.67]), obesity (OR = 2.36, 95% CI = [1.52–3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46–3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43–3.06] for EDSS 3–5.5 and OR = 4.53, 95% CI = [3.04–6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85–3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60–0.69]) or off (RR = 0.32, 95% CI = [0.30–0.33]) anti-CD20. Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.

---

Fichiers liés : covisep_hal.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2024
• Auteurs : Lloyd IzardNadège FonvieilleCamille MerlandPhilippe KoubbiDavid NeriniJérémie HabasqueAnne Lebourges-DhaussyClaire Lo MonacoGildas RoudautFrancesco d'OvidioJean-Benoît CharrassinCédric Cotté
• Organismes : Processus et interactions de fine échelle océanique Institut méditerranéen d'océanologie Sorbonne Université - Faculté des Sciences et ingénierie - UFR Terre, Environnement, Biodiversité Laboratoire Ressources Halieutiques de Boulogne Sorbonne Université - Faculté des Sciences et ingénierie - UFR Terre, Environnement, Biodiversité Institut méditerranéen d'océanologie Laboratoire des Sciences de l'Environnement Marin (LEMAR) Laboratoire des Sciences de l'Environnement Marin (LEMAR) Cycles biogéochimiques marins : processus et perturbations Laboratoire des Sciences de l'Environnement Marin (LEMAR) Processus et interactions de fine échelle océanique Processus et interactions de fine échelle océanique Processus et interactions de fine échelle océanique
• Publié dans Journal of Marine Systems le 25/10/2020

---

Résumé : The pelagic zone is home to a large diversity of organisms such as macrozooplankton and micronekton (MM), connecting the surface productive waters to the mesopelagic layers (200-1000 m) through diel vertical migrations (DVM). Active acoustics complement net sampling observations by detecting sound-scattering layers (SL) of organisms, allowing to monitor the MM dynamics with a high spatio-temporal resolution. Multifrequency analyses are a pertinent approach to better integrate the rich diversity of organisms composing SLs and their respective dynamics. However, analysing simultaneously emitted acoustic signals with distinct depth ranges and separating spatial from temporal variability is challenging and needs adapted tools to be fully exploited. This study examines the pelagic realm in a transition zone between the Southern Ocean and the subtropical Indian Ocean, crossing the Saint-Paul and Amsterdam islands' natural reserve. We extended a Multivariate Functional Principal Component Analysis (mfPCA) to analyse the joint vertical variation of five frequencies from two oceanographic cruises (2016 and 2022), allowing the decomposition of the acoustic dataset into orthogonal vertical modes (VM) of variability. We found the first VM to be linked to the temporal variability due to DVM, while the following majorly depict patterns in spatial distribution. Overall, from the subantarctic to the subtropical zones, we observed (i) enrichment of densities in the surface layer (0-100 m), (ii) a decrease in densities in the intermediate layer during the daytime (100-300 m) and (iii) the apparition of an intensive deep scattering layer on the 38 kHz. We explored VMs' connection with in -situ environmental conditions by clustering our observations into three distinct environmental-acoustic regions. These regions were compared with vertically integrated nautical area scattering coefficient distribution, a proxy for marine organisms' biomass. Additionally, we analysed species assemblage changes from complementary cruises to further elucidate the observed acoustic distribution. We show that the mfPCA method is promising to better integrate the pelagic horizontal, vertical and temporal dimensions which is a step towards further investigating the control of the environment on the distribution and structuring of pelagic communities.

---

Fichiers liés : Full_text_MarSys.pdf

---

Source

---

• Type de publi. : Autre publication
• Date de publi. : 01/03/2024
• Auteurs : Ewen MullinsJean‐louis BressonTamas DalmayIan Crawford DewhurstMichelle EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoFrancisco Javier MorenoHanspeter NaegeliFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiMichele ArdizzoneAna CamargoGiacomo de SanctisSilvia FedericiAntonio FernandezAndrea GennaroJosé Ángel Gómez RuizTilemachos GoumperisPaschalina GrammatikouDafni Maria KagkliPaolo LenziFranco Maria NeriNikoletta PapadopoulouTommaso Raffaello
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Source